Valuation: Biocorrx Inc

Market Cap 9.88M 8.64M 7.97M 7.37M 14M 942M 14.23M 95.34M 37.38M 464M 37.09M 36.28M 1.6B P/E 2024
-0.78x
P/E 2025 -1.56x
Enterprise Value 11.88M 10.39M 9.58M 8.86M 16.83M 1.13B 17.12M 115M 44.95M 558M 44.6M 43.63M 1.93B EV / Sales 2024
1,004x
EV / Sales 2025 11.4x
Free-Float
38.64%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 08/11/2020
President 77 04/01/2024
Director TitleAgeSince
Director/Board Member 58 06/03/2013
Chairman 57 -
Director/Board Member 77 28/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-15.84%+6.09% - - 11.62M
-1.59%-1.91%+53.59%+48.63% 133B
-0.39%+4.01%+8.32%+40.32% 91.09B
-0.42%+2.90%+0.55%+71.35% 27.23B
-0.08%-3.69%+20.61%+49.68% 23.05B
-1.75%-1.11%-20.93%-25.61% 20.25B
+0.25%+8.14%+19.94%+158.27% 17.77B
-0.54%+0.64%+59.58%+120.89% 14.81B
+3.14%-1.07%+3.29%+10.78% 14.51B
-0.38%+4.37%-11.32%-2.43% 12.86B
Average -1.56%+1.73%+14.85%+52.43% 39.43B
Weighted average by Cap. +0.02%+1.58%+25.66%+49.18%

Financials

2024 2025
Net sales 7.66K 6.7K 6.18K 5.72K 10.86K 731K 11.04K 73.97K 29K 360K 28.78K 28.15K 1.24M 797K 697K 643K 594K 1.13M 76.04M 1.15M 7.69M 3.02M 37.42M 2.99M 2.93M 129M
Net income -5.11M -4.47M -4.12M -3.81M -7.23M -487M -7.36M -49.28M -19.32M -240M -19.17M -18.75M -829M -3.44M -3.01M -2.77M -2.57M -4.87M -328M -4.96M -33.2M -13.02M -161M -12.91M -12.63M -559M
Net Debt 2.72M 2.38M 2.19M 2.03M 3.85M 259M 3.92M 26.23M 10.28M 128M 10.2M 9.98M 441M 2M 1.75M 1.61M 1.49M 2.84M 191M 2.88M 19.31M 7.57M 93.92M 7.51M 7.35M 325M
Logo Biocorrx Inc
BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
Employees
-